Results for tag: "Opiod Induced Constipation Drugs"

The opioid-induced constipation (OIC) drugs market is a specialized segment within the broader gastrointestinal drugs market, which encompasses a range of medications designed to treat various conditions that affect the gastrointestinal system, including constipation, which is a common side effect of opioid analgesics. Opioid analgesics are widely used to manage moderate to severe pain, but they often have the adverse effect of inhibiting bowel motility, leading to OIC. OIC drugs are specifically formulated to counteract this effect and provide relief from constipation without disrupting the analgesic effects of opioids. OIC medications include several types of drugs, such as peripherally acting μ-opioid receptor antagonists, which work by selectively blocking the opioid receptors in the gut to restore bowel function, and stool softeners that help relieve constipation by different mechanisms of action. These targeted therapies are designed to improve the quality of life for patients under opioid treatment by managing one of the most discomforting side effects. As patients using long-term opioid therapy for chronic conditions such as cancer-related pain or non-cancer pain are prone to developing OIC, the demand for effective management solutions is a consistent concern within the field of gastrointestinal drugs. Some key players in the opioid-induced constipation drugs market include AstraZeneca, with their drug Movantik® (naloxegol), Takeda Pharmaceutical Company's Amitiza® (lubiprostone), and Bausch Health's Relistor® (methyln Show Less Read more